Lipid-Modifying Agents

2020 ◽  
pp. 220-240
Author(s):  
Mark D. Mamrack
Keyword(s):  
Lipid Modifying Agents

scholarly journals PCV69 Consumption Volume of Plain Lipid Modifying Agents of the Statin Group on the Ukrainian Pharmaceutical Market during 2015-2018

2020 ◽  
Vol 23 ◽  
pp. S499
Author(s):  
L. Iakovlieva ◽  
L. Shuliak ◽  
O. Berdnyk ◽  
N. Bezditko ◽  
O. Tkachova ◽  
...  
Keyword(s):  
Pharmaceutical Market ◽  
Statin Group ◽  
Lipid Modifying Agents

scholarly journals Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases

2021 ◽  
Vol 11 (8) ◽  
pp. 820
Author(s):  
Mengyuan Ge ◽  
Sandra Merscher ◽  
Alessia Fornoni
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Recent Progress ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Glomerular Diseases ◽  
Intracellular Lipids ◽  
Lipid Modifying Agents ◽  
Made In

Although dyslipidemia is associated with chronic kidney disease (CKD), it is more common in nephrotic syndrome (NS), and guidelines for the management of hyperlipidemia in NS are largely opinion-based. In addition to the role of circulating lipids, an increasing number of studies suggest that intrarenal lipids contribute to the progression of glomerular diseases, indicating that proteinuric kidney diseases may be a form of “fatty kidney disease” and that reducing intracellular lipids could represent a new therapeutic approach to slow the progression of CKD. In this review, we summarize recent progress made in the utilization of lipid-modifying agents to lower renal parenchymal lipid accumulation and to prevent or reduce kidney injury. The agents mentioned in this review are categorized according to their specific targets, but they may also regulate other lipid-relevant pathways.

Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012

2014 ◽  
Vol 21 (3) ◽  
pp. 143-150
Author(s):  
Ingrida Lisauskienė ◽  
Kristina Garuolienė ◽  
Jolanta Gulbinovič
Keyword(s):  
Antihypertensive Drugs ◽  
Renin Angiotensin System ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Insurance Fund ◽  
Channel Blockers ◽  
Prescribing Pattern ◽  
Converting Enzyme Inhibitors ◽  
Mortality And Morbidity ◽  
High Consumption ◽  
Lipid Modifying Agents

Background. Despite the wide use of cardiovascular (CV) drugs, CV diseases are still the leading cause of mortality and morbidity. Analysis of drug utilization gives a possibility to evaluate effectiveness of interventions. Materials and methods. The aim of the study was to evaluate CV medicines consumption in Lithuania in 2003–2012. Data was retrieved from the SVEIDRA database of the National Health Insurance Fund. Utilization of the following groups of CVM (ATC group C) was analyzed: C02 – antihypertensive drugs, C03 – diuretics, C07 – beta blocking agents (BBs), C08 – calcium channel blockers (CCBs), C09 – agents acting on the renin–angiotensin system, C10 – lipid modifying agents. ATC/DDD methodology was used. Data was expressed as a number of DDD per 1  000 inhabitants per day (DDD/TID). Results. Consumption of CVM went from 134.5 DDD/TID in 2003 to 352.2 in 2012. Angiotensin converting enzyme inhibitors (ACEI) were the most consumed ones (66–114.8 DDD/TID), followed by CCBs (19.4–38.8 DDD/TID) and BBs (12.5–52.6 DDD/TID).There was high consumption of antihypertensives (4.7–23.9 DDD) and low consumption of diuretics (9.4–16.9 DDD/TID) and lipid modyfing agents (0.4–7.4 DDD/TID). Increasing utilization was noticed in the angiotensin II antagonist (ARBs) group (42 DDD/TID), ACEI combinations (38.6 DDD/TID) and ARBs combinations (12.9 DDD/TID) in 2012. Conclusions. Utilization of CV medicines increased in Lithuania in 2003–2012. ACEI held the first position. An extremely low utilization of lipid modifying agents, diuretics and high consumption of alpha-receptor blockers showed the need of actions on changing the prescribing pattern of CV drugs.

scholarly journals The use of anti-hyperlipidemia in a private hospital in Yogyakarta during 2013-2019

2021 ◽  
Vol 17 (2) ◽  
pp. 173-181
Author(s):  
Yosi Febrianti ◽  
Saepudin Saepudin ◽  
Dian Medisa ◽  
Haryo Tetuko ◽  
Nurul Fadhillah Hasanah
Keyword(s):  
Hospital Pharmacy ◽  
Private Hospital ◽  
Fold Increase ◽  
Hospitalized Patients ◽  
Defined Daily Dose ◽  
Primary And Secondary Prevention ◽  
Pharmacy Department ◽  
Daily Dose ◽  
Bed Days ◽  
Lipid Modifying Agents

Background: Lipid modifying agents have an important role in the primary and secondary prevention of cardiovascular diseases such as coronary heart disease and stroke. The use of lipid-modifying agents tends to increase along with the increasing prevalence of these diseases. Objectives: To determine the utilization of lipid modifying agents for hospitalized patients in a private hospital in Yogyakarta during the period of 2013 - 2019 in regard to the agents used and their quantity. Methods: The main data for this study were aggregate data on the use of lipid modifying agents for hospitalized patients during 2013-2019 obtained from the hospital pharmacy department. After identification of the names of lipid modifying agents, the quantities of these drugs were then calculated in units of defined daily dose (DDD) and the final quantity was expressed in DDD/100 bed days (BD). The R2 value from linear regression was used to determine the trend of use of individual agents over the period. Results: There were two pharmacological subgroups of lipid modifying agents used during the period of 2013 – 2019 with an average of total quantity of 14.81 DDD/100 BD. Utilization of statins was approximately 90% of the total use, and utilization of fibrates tended to decrease over the period. Individually, simvastatin use decreased significantly over the period (R2 = 0.885), but atorvastatin use continued to increase (R2 = 0.908) with 10-fold increase from 2013 to 2019. Conclusion: The lipid modifying agents used during the period 2013 - 2019 were predominantly statins, and the utilization of atorvastatin increased significantly during this period. Keywords: lipid modifying agents, ATC/DDD, fibrates, statins

scholarly journals Prevalence of corneal arcus and associated factors in a German population—Results from the Gutenberg Health Study

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0255893
Author(s):  
Joanna Wasielica-Poslednik ◽  
Ulrike Hampel ◽  
Lisa Ries ◽  
Ruah Faysal ◽  
Andreas Schulz ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Blood Pressure ◽  
Associated Factors ◽  
Economic Status ◽  
Anterior Segment ◽  
Health Study ◽  
Socio Economic Status ◽  
Gutenberg Health Study ◽  
Arterial Blood ◽  
Lipid Modifying Agents

Purpose We aimed to determine the prevalence of corneal arcus and to identify associated factors in the general population of Germany. Methods The Gutenberg Health Study (GHS) is a population-based cohort study in Germany, which includes an ophthalmological assessment. Refraction, distance-corrected visual acuity, non-contact tonometry and anterior segment imaging were performed for the five-year follow-up examination. Anterior segment photographs were graded for the presence of corneal arcus. Prevalence estimates were computed, and multivariable logistic regression analysis was applied to determine associated factors for corneal arcus including sex, age, spherical equivalent, central corneal thickness, intraocular pressure (IOP), socio-economic status, smoking, BMI, systolic and diastolic arterial blood pressure, HbA1c, HDL-C, LDL-C, triglyceride, and lipid modifying agents. Results A total of 9,850 right and 9,745 left eyes of 9,858 subjects (59.2±10.8 years), 49.0% females were included in this cross-sectional analysis. 21.1% of men (95%-CI: 20.0%– 22.3%) had a corneal arcus in at least one eye, and 16.9% (95%-CI: 15.9%– 18.0%) of women. In multivariable analyses, the presence of corneal arcus was associated with male gender (OR = 0.54 for female, p<0.0001), higher age (OR = 2.54 per decade, p<0.0001), smoking (OR = 1.59, p<0.0001), hyperopia (OR = 1.05 per diopter, p<0.0001), thinner cornea (OR = 0.994 per μm, p<0.0001), higher IOP (OR = 1.02, p = 0.039), higher HDL-C-level (OR = 2.13, p<0.0001), higher LDL-C-level (OR = 1.21, p<0.0001), and intake of lipid modifying agents (OR = 1.26, p = 0.0001). Arcus was not associated with socio-economic status, BMI, arterial blood pressure, and HbA1c. Conclusions Corneal arcus is a frequent alteration of the cornea in Germany and is associated with ocular parameters and systemic parameters of dyslipidemia.

Current lipid-modifying agents

2015 ◽  
Vol 16 (7) ◽  
pp. 1117-1118 ◽  
Author(s):  
Aris P Agouridis ◽  
Theodosios D Filippatos ◽  
Niki Katsiki
Keyword(s):  
Lipid Modifying Agents
Sign in / Sign up

Export Citation Format

Share Document